Garland Kgosi More | Pharmacology | Best Researcher Award

Published on 28/03/202528/03/2025 by Global Academic Awards

Dr. Garland Kgosi More | Pharmacology | Best Researcher Award

Dr. Garland Kgosi More, University of South Africa, South Africa

Dr. Garland Kgosi More is a distinguished agricultural scientist specializing in medicinal plant research, particularly in combating infectious diseases. With a PhD in Agriculture from the University of South Africa (UNISA) and a Master’s in Medicinal Plant Sciences from the University of Pretoria (UP), he has made significant contributions to antiviral, antimicrobial, and phytochemical studies. His groundbreaking research on in vitro anti-Rift Valley Fever Virus and medicinal plant metabolomics has earned him international recognition. Currently, Dr. More serves as a Chief Laboratory Technologist and Senior Lecturer at UNISA, contributing to academic excellence through teaching, supervision, and extensive research. His work is widely published in esteemed journals, and he actively mentors postgraduate students. He is passionate about using indigenous knowledge for modern therapeutic solutions and continues to advance global health through innovative scientific inquiry. 🌿🧬

Publication Profile

scopus

Orcid

Google Scholar

🎓 Education

Dr. Garland Kgosi More earned his Doctor of Philosophy in Agriculture from UNISA in 2021, specializing in in vitro anti-Rift Valley Fever Virus research using 1H-NMR metabolomics. His Master of Science in Medicinal Plant Sciences from UP, awarded with distinction in 2013, focused on the antimicrobial constituents of Artemisia afra against periodontal pathogens. In 2007, he completed his Bachelor of Science Honours in Botany, exploring the antimicrobial properties of medicinal plants targeting oral microorganisms. Prior to this, he obtained a Bachelor of Science in Natural/Biological Sciences from UP in 2006, majoring in Botany and Zoology. Committed to professional development, he pursued certifications in Project Management (2020), Hazardous Chemical Substance Handling (2012), HIV/AIDS Awareness (2009), and Occupational Health and Safety Legislation (2008). His interdisciplinary education has equipped him with a robust foundation in agricultural research, biotechnology, and medicinal plant pharmacology. 🧪🌱

💼 Experience

Dr. Garland Kgosi More has over 15 years of academic and research experience. Currently serving as Chief Laboratory Technologist and Senior Lecturer at UNISA, he provides technical expertise, leads laboratory operations, supervises postgraduate students, and conducts high-impact research. He previously held positions as a Laboratory Technologist at UNISA (2014–2023) and Laboratory Technician at UP (2008–2014). In these roles, he managed high-containment laboratories, implemented safety protocols, and supported undergraduate and postgraduate research. His extensive experience includes research project management, laboratory quality control, and the development of standard operating procedures. He has also contributed to health and safety compliance, waste management, and the application of advanced analytical techniques like NMR and UHPLC-MS. Beyond academia, Dr. More actively engages in community outreach projects, promoting scientific knowledge and empowering emerging researchers. His leadership and dedication have significantly advanced agricultural and medicinal plant research. 🧬📊

🏅 Awards and Honors

Dr. Garland Kgosi More has been recognized for his outstanding contributions to agricultural and medicinal plant sciences. His achievements include publishing in prestigious journals like Scientific Reports, Viruses, and MDPI Antioxidants. His doctoral research on antiviral compounds using NMR metabolomics has earned international acclaim. He has received accolades for mentoring postgraduate students and contributing to their successful research publications. Dr. More has served on academic committees, peer-reviewed journals, and research councils, demonstrating academic leadership. He has also presented at numerous international conferences, sharing insights on medicinal plant pharmacology and disease management. His collaborations with multidisciplinary researchers globally further highlight his dedication to scientific advancement. Committed to public health, he has supported projects addressing infectious diseases like HIV and tuberculosis. Dr. More’s accolades exemplify his unwavering commitment to research excellence and societal impact. 🏆🌿

🔎 Research Focus

Dr. Garland Kgosi More’s research revolves around agricultural biotechnology, phytochemistry, and medicinal plant sciences. His primary focus is the identification and analysis of bioactive compounds from medicinal plants for antiviral, antimicrobial, and anti-inflammatory applications. Using advanced metabolomics, including 1H-NMR and UHPLC-MS, he investigates the therapeutic potential of indigenous South African flora. His studies on antiviral agents against the Rift Valley Fever Virus and antimicrobial properties of Artemisia afra have made significant strides in infectious disease management. Additionally, he explores nanotechnology applications in plant-based drug development and investigates the pharmacological effects of nanoparticles synthesized from plant extracts. His multidisciplinary approach includes in silico modeling, molecular docking studies, and cytotoxicity evaluations. Through his extensive research, Dr. More aims to bridge traditional medicine with modern pharmacology, contributing to the discovery of innovative treatments for viral infections and antimicrobial resistance. 🌿🔬

Publication Top Notes

📚 Antimicrobial activity of medicinal plants against oral microorganisms – Cited by 242, 2008 🦷🌿
📚 In-vitro analysis of free radical scavenging activities and suppression of LPS-induced ROS production in macrophage cells by Solanum sisymbriifolium extracts – Cited by 119, 2020 🧪🛡️
📚 Antimicrobial Constituents of Artemisia afra Jacq. ex Willd. against Periodontal Pathogens – Cited by 83, 2012 🌿🦷
📚 Novel silver-platinum bimetallic nanoalloy synthesized from Vernonia mespilifolia extract: Antioxidant, antimicrobial, and cytotoxic activities – Cited by 64, 2020 🧬🦠
📚 Antimicrobial, antioxidant, and cytotoxic properties of biosynthesized copper oxide nanoparticles (CuO-NPs) using Athrixia phylicoides DC – Cited by 46, 2023 🧪🦠
📚 Alkaloids from aerial parts of Annona senegalensis against Streptococcus mutans – Cited by 41, 2017 🌿🧬
📚 A review of the ethnopharmacology, phytochemistry and pharmacological relevance of the South African weed Solanum sisymbriifolium Lam. (Solanaceae) – Cited by 29, 2019 📖🌱
📚 Synthesis of furocoumarin–stilbene hybrids as potential multifunctional drugs against multiple biochemical targets associated with Alzheimer’s disease – Cited by 23, 2020 🧠💊
📚 Metabolomic profile of medicinal plants with anti-RVFV activity – Cited by 19, 2022 🦠🧬
📚 Metabolomic Profiling of Antioxidant Compounds in Five Vachellia Species – Cited by 18, 2021 🌳🛡️
📚 In vitro evaluation of anti-Rift Valley Fever Virus, antioxidant and anti-inflammatory activity of South African medicinal plant extracts – Cited by 18, 2021 🦠🧪
📚 Lithium inhibits NF-κB nuclear translocation and modulates inflammation profiles in Rift Valley Fever virus-infected Raw 264.7 macrophages – Cited by 16, 2021 🧫🛡️
📚 Bio-synthesized calcium carbonate (CaCO3) nanoparticles: Their anti-fungal properties and application as nanofertilizer on Lycopersicon esculentum growth and gas exchange – Cited by 14, 2023 🍅🌿
📚 Design, synthesis and evaluation of the 2′-hydroxy-3′-iodo-5′-nitrochalcones for cytotoxicity (MCF-7 & A549) and potential to inhibit tyrosine kinase (VEGFR-2) activity – Cited by 12, 2024 🧪🧬
📚 Antimicrobial, cytotoxic and oxidative stress inhibitory activities of terpenoids and flavonols from Senegalia nigrescens (Oliv.) PJH Hurter – Cited by 9, 2021 🌿🧫

Conclusion 🏆

Dr. Garland Kgosi More is a highly suitable candidate for the Best Researcher Award. His exceptional academic background, impactful research in antiviral and antimicrobial compounds, significant publication record, commitment to student mentorship, and leadership in scientific research position him as a strong contender for this prestigious recognition.

Bikash khadka | Medicine and Dentistry | Best Researcher Award

Published on 10/12/202410/12/2024 by Global Academic Awards

Dr. Bikash khadka | Medicine and Dentistry | Best Researcher Award

Dr. Bikash khadka , Nepal Mediciti , Nepal

Dr. Bikash Khadka is a dedicated anesthesiologist from Lalitpur, Kathmandu, Nepal, with extensive experience in critical care and perioperative medicine. He earned his MD in Anesthesiology from Lumbini Medical College, affiliated with Kathmandu University, in 2018, after completing his MBBS at Kathmandu University School of Medical Sciences in 2012. Dr. Bikash Khadka currently serves as a Junior Consultant Anesthesiologist at Nepal Mediciti Hospital, where he manages a 32-bed mixed ICU and conducts anesthesia for various surgeries. Passionate about medical education, he has also served as a Lecturer at Lumbini Medical College. His research focuses on anesthesia techniques, critical care, and perioperative safety, with numerous published articles in peer-reviewed journals. He is proficient in advanced airway management, regional blocks, and critical patient care. Dr. Bikash Khadka actively participates in medical workshops and conferences to stay updated in his field.

Publication Profile

Scopus

Work Experience

Dr. Bikash Khadka has been a Junior Consultant Anesthesiologist at Nepal Mediciti Hospital since August 2019, where he manages a 32-bed mixed ICU and provides anesthesia for diverse surgeries. From November 2018 to August 2019, he worked as a Lecturer at Lumbini Medical College, teaching anesthesiology to medical students. As a Resident Doctor (2015-2018) at the same institution, he performed pre-anesthetic assessments, anesthesia conduction, ICU management, and supervised junior residents. His responsibilities included emergency surgeries, obstetric analgesia, and critical care. From September 2013 to March 2014, he was a Medical Officer at Alka Hospital, providing emergency care. His experience spans specialized anesthesia services, resuscitation, and managing patients across various surgical and ICU settings.

Education and Training

Dr. Bikash Khadka earned his MD in Anesthesiology from Lumbini Medical College, affiliated with Kathmandu University, from 2015 to 2018. Prior to that, he completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at Kathmandu University School of Medical Sciences between 2008 and 2012. During his medical education, he acquired extensive theoretical knowledge and hands-on experience, laying the foundation for his career in anesthesiology and critical care. His education focused on pre-anesthetic assessment, anesthesia conduction, ICU management, and patient care during complex surgical procedures. Dr. Bikash Khadka also completed significant training, including ACLS, BLS, airway management, and acute care ultrasound workshops, strengthening his proficiency in both clinical and emergency care. His commitment to continual learning is reflected in his active participation in national conferences and specialized courses.

Awards and Training

Dr. Bikash Khadka has attended various prestigious conferences and workshops, including the 17th National Conference of the Society of Anesthesiologists of Nepal (SANCON) in 2016. He participated in specialized workshops like the Difficult Airway Workshop and Acute Care Ultrasound Workshop. He holds certifications in Advanced Cardiovascular Life Support (ACLS) and Basic Life Support (BLS), showcasing his dedication to critical care excellence. His commitment to academic excellence is evident through his lecturer role and involvement in training junior residents. Dr. Bikash Khadka’s clinical expertise and research contributions have established him as a respected professional in anesthesiology and critical care in Nepal.

Research Focus

Dr. Bikash Khadka’s research focuses on anesthesiology, critical care, and perioperative management. His interests include optimizing patient outcomes in ICU settings, managing complex airway cases, and preventing anesthesia-related complications. He has contributed to research on rare medical conditions, such as Boerhaave syndrome and post-COVID-19 vaccine complications. Dr. Bikash khadka is also interested in comparative studies on pharmacological agents to improve surgical outcomes, such as using dexmedetomidine and dexamethasone for postoperative nausea prevention. His work often explores innovative approaches to regional anesthesia, patient safety, and critical care protocols. His systematic reviews and case reports provide valuable insights into anesthesia practice and patient management.

Publication Top Notes

Role of pre-operative counseling with NSQIP surgical risk calculator in the surgical patients

Authors: Khadka, B., Sharma, A., Bhattarai, P.R., Rayamajhi, B., Adhikari, H.

Journal: Surgery Open Science

Year: 2024

Volume: 18, pp. 11–16

Citations: 0

Pyopericardium progressing to cardiac tamponade in a patient with dengue fever

Authors: Khadka, B., Khanal, K., Regmi, A., KC, S., Nepal, R.

Journal: IDCases

Year: 2024

Volume: 36, Article e01996

Citations: 0

Removing knotted or stuck epidural catheters: a systematic review of case reports

Authors: Khadka, B., Sharma, A., Regmi, A., Ghimire, A., Bhattarai, P.R.

Journal: Anesthesia and Pain Medicine

Year: 2023

Volume: 18(3), pp. 315–324

Citations: 1

A rare case of Boerhaave syndrome with cervico-thoracic esophageal junction rupture causing bilateral empyema; case report from Nepal

Authors: Khadka, B., Khanal, K., Dahal, P., Adhikari, H.

Journal: International Journal of Surgery Case Reports

Year: 2023

Volume: 105, Article 108018

Citations: 2

Post COVID-19 vaccine Guillain-Barré syndrome

Authors: Khadka, B., Khanal, K.

Journal: Journal of Nepal Health Research Council

Year: 2022

Volume: 19(4), pp. 852–854

Citations:

Chun-Feng Huang | Health Professions | Best Researcher Award

Published on 26/11/202426/11/2024 by Global Academic Awards

Assist. Prof. Dr. Chun-Feng Huang | Health Professions | Best Researcher Award

Chief of Family Medicine at En Chu Kong Hospital/National Yang Ming Chiao Tung University, Taiwan

Dr. Chun-Feng Huang is an Assistant Professor at the National Yang Ming Chiao Tung University and the Chief of Family Medicine at En Chu Kong Hospital. With a rich academic background, including a Ph.D. from Taipei Medical University and an MD from National Yang Ming Chiao Tung University, Dr. Huang is a certified expert in Family Medicine, Hospice and Palliative Medicine, and Osteoporosis. His research spans metabolomics, precision medicine, gerontology, and osteoporosis, with numerous publications in reputable journals. 🌊🔬.

Publication Profile

Education

Dr. Chun-Feng Huang earned his Doctor of Medicine degree from the National Yang Ming Chiao Tung University, School of Medicine, Taiwan. He further specialized by obtaining a Ph.D. from Taipei Medical University’s Graduate Institute of Clinical Medicine. Complementing his advanced education, Dr. Huang holds various board certifications: Family Medicine, Hospice and Palliative Medicine, Integrative Medicine, and Osteoporosis. Additionally, he is a Certified Clinical Densitometrist accredited by the International Society for Clinical Densitometry (ISCD). His academic journey reflects a deep commitment to continuous learning and specialization in both clinical and research domains, equipping him with a robust foundation to tackle complex medical challenges. Dr. Huang’s educational background not only highlights his expertise in medicine but also underscores his dedication to advancing patient care through education, research, and clinical excellence.

Experience

Dr. Chun-Feng Huang’s career is marked by influential roles in academia and clinical practice. He currently serves as an Assistant Professor at the National Yang Ming Chiao Tung University and Chief of the Department of Family Medicine at En Chu Kong Hospital. Previously, he directed the Department of Family Medicine at the same university hospital from 2016 to 2022. His leadership extended to chairing healthcare services for correctional institutions and community development associations. As Deputy Secretary General and former Prevention Committee Deputy Chairman of the Taiwan Association of Family Medicine, Dr. Huang has shaped national health policies. He also contributed as a Director for the Taipei Smart City IoT Association. His experience in reviewing medical policies for Taiwan’s FDA and involvement in mountain healthcare projects demonstrates his dedication to improving public health systems and addressing diverse healthcare needs through integrated solutions.

Awards and Honors

Dr. Chun-Feng Huang has received numerous accolades for his contributions to medicine and community health. He was recognized with the First Prize at the Annual Academic Conference by the Taiwan Association of Family Medicine in both 2011 and 2018. Between 2010 and 2017, he served as the Principal Investigator for key projects, including the Mountain and Offshore Healthcare Plan and healthcare services for correctional institutions. His leadership was also acknowledged as Chairman of the Yilan County Kang Tai Community Development Association and as Director of the Taipei Smart City IoT Association. His continuous service to healthcare is highlighted by his role as a reviewer for the Taiwan Food and Drug Administration. These awards and honors underscore his commitment to innovation, excellence in family medicine, and the advancement of public health initiatives.

Research Focus

Dr. Chun-Feng Huang’s research centers on metabolomics, precision medicine, gerontology, and osteoporosis. He explores the intricate connections between metabolic pathways and chronic diseases, aiming to develop personalized medical interventions. His work in precision medicine emphasizes tailoring treatments to individual genetic and environmental factors, particularly for elderly populations. In gerontology, he focuses on improving quality of life and functional health outcomes, with a special interest in sarcopenia and cognitive decline. Dr. Huang is also a leading expert in osteoporosis research, contributing to guidelines for fracture prevention and management. His studies include the effects of medications on bone health and the development of innovative treatments to reduce mortality in osteoporosis patients. Through multidisciplinary collaborations, he aims to bridge clinical research with practical healthcare solutions, advancing the understanding and management of age-related diseases.

Conclusion

Dr. Chun-Feng Huang is an outstanding candidate for the Best Researcher Award. His prolific research output, leadership roles, and clinical impact demonstrate excellence and dedication. Addressing the suggested areas for improvement could further elevate his contributions, but his current achievements already position him as a leading figure in his field.

Publication Top Notes

Nicotinuric acid: a potential marker of metabolic syndrome through a metabolomics-based approach

Authors: CF Huang, ML Cheng, CM Fan, CY Hong, MS Shiao

Citations: 57

Year: 2013

Effects of incorporating multidomain interventions into integrated primary care on quality of life: a randomised controlled trial

Authors: WJ Lee, LN Peng, CH Lin, RC Chen, SZ Lin, CH Loh, SL Kao, TS Hung, …

Citations: 55

Year: 2021

Heat stress responses modulate calcium regulations and electrophysiological characteristics in atrial myocytes

Authors: YC Chen, YH Kao, CF Huang, CC Cheng, YJ Chen, SA Chen

Citations: 38

Year: 2010

Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: 2022 update

Authors: TW Tai, CF Huang, HK Huang, RS Yang, JF Chen, TT Cheng, FP Chen, …

Citations: 29

Year: 2023

Treatment of osteoporosis after hip fracture is associated with lower all-cause mortality: a nationwide population study

Authors: TW Tai, CC Li, CF Huang, WP Chan, CH Wu

Citations: 24

Year: 2022

Mononucleated and binucleated cardiomyocytes in left atrium and pulmonary vein have different electrical activity and calcium dynamics

Authors: CF Huang, YC Chen, HI Yeh, SA Chen

Citations: 22

Year: 2012

Pharmacologic intervention for prevention of fractures in osteopenic and osteoporotic postmenopausal women: Systemic review and meta-analysis

Authors: CH Wu, WC Hung, L Chang, TT Tsai, YF Chang, EV McCloskey, NB Watts, …

Citations: 19

Year: 2020

Retrospective study of the effects of zoledronic acid on muscle mass in osteoporosis patients

Authors: CF Huang, MS Shiao, TY Mao

Citations: 17

Year: 2021

Detection of ventilatory thresholds using near-infrared spectroscopy with a polynomial regression model

Authors: CW Lin, CF Huang, JS Wang, LL Fu, TY Mao

Citations: 15

Year: 2020

First insights on value-based healthcare of elders using ICHOM older person standard set reporting

Pedro Antonio Regidor | Medicine and Dentistry | Best Innovation Award

Published on 18/09/202430/08/2025 by Global Academic Awards

Dr. Pedro Antonio Regidor | Medicine and Dentistry | Best Innovation Award

Dr. Pedro Antonio Regidor, Exeltis, Germany

Dr. Pedro Antonio Regidor holds dual German and Spanish citizenship. He completed his medical studies at the University of Essen and gained extensive experience in gynecology and obstetrics across Germany and Venezuela. Notably, he served as Medical Director at Exeltis Europe and Global Projects. His qualifications include specialized certifications in radiological diagnostics and gynecological endocrinology. Dr. Regidor is recognized for his contributions to women’s health and medical innovation. Currently, he continues his work as a Medical Director and private practitioner in Munich, Germany. 🌍💉

Publication profile

Scopus

Professional Background

Dr. Pedro Antonio Regidor, holding both German and Spanish citizenship, has a distinguished career in the field of gynecology and obstetrics. His educational journey began at the Deutsche Schule Madrid and continued with medical studies at the University of Essen, where he completed his state exams and medical training. His professional experience spans multiple countries and prestigious institutions, including roles as a senior physician and medical director at prominent medical centers in Germany.

Innovative Contributions

Dr. Regidor has demonstrated a commitment to advancing medical practice and patient care. His roles in various high-profile positions, including Medical Director at Exeltis Europe & Global Projects, reflect his leadership in implementing innovative practices and advancing healthcare delivery. His experience with cutting-edge medical technologies and practices, including his certifications in advanced diagnostic and therapeutic techniques, underscores his contributions to medical innovation.

Awards and Recognitions

Dr. Regidor’s career is marked by several significant recognitions, including his certifications in specialized fields such as radiological diagnostics and gynecological endocrinology. His role as a Medical Director involved overseeing global projects, indicating a strong track record of managing and implementing innovative solutions across diverse healthcare settings.

Publication Top Notes

“The drospirenone only pill as a contraceptive option for breastfeeding women: First data on users’ acceptability and newborn development” (Gynecological Endocrinology, 2024) 📅
“OPEN PROSPECTIVE STUDY TO EVALUATE THE EFFICACY OF A NEW VAGINAL PESSARY CONTAINING 300MG TINIDAZOLE, 200MG TIOCONAZOLE AND 100MG LIDOCAINE” (Reproductive Endocrinology, 2024) 📅
“Nausea and Vomiting of Pregnancy and its Management with the Dual-Release Formulation of Doxylamine and Pyridoxine” (Geburtshilfe und Frauenheilkunde, 2023) 📅
“Improvement in menopausal symptoms with a nutritional product containing evening primrose oil, hop extract, saffron, tryptophan, vitamins B6, D3, K2, B12, and B9” (European Review for Medical and Pharmacological Sciences, 2023) 📅
“10-month retrospective study on compliance and tolerability of the drospirenone-only pill” (European Review for Medical and Pharmacological Sciences, 2023) 📅
“Miconazole for the treatment of vulvovaginal candidiasis. In vitro, in vivo and clinical results. Review of the literature” (Journal of Obstetrics and Gynaecology, 2023) 📅
“Pharmacological and metabolic effects of drospirenone as a progestin-only pill compared to combined formulations with estrogen” (Women’s Health, 2023) 📅
“The drospirenone (DRSP)-only pill: clinical implications in the daily use” (European Journal of Contraception and Reproductive Health Care, 2023) 📅
“Erratum: Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone” (Geburtshilfe und Frauenheilkunde, 2022) 📅
“Evaluation of the food effect on a drospirenone only contraceptive containing 4 mg administered with and without high-fat breakfast in a randomised trial” (BMC Women’s Health, 2022) 📅

Conclusion

Dr. Pedro Antonio Regidor’s extensive experience in gynecology, his leadership in implementing innovative healthcare practices, and his significant contributions to medical advancements, he is a strong candidate for the “Research for Best Innovation Award.” His career reflects a profound impact on medical practices and innovation, aligning well with the award’s criteria.

Cristina Papayannidis | Medicine and Dentistry | Best Researcher Award

Published on 23/08/202423/08/2024 by Global Academic Awards

Cristina Papayannidis | Medicine and Dentistry | Best Researcher Award

Dr Cristina Papayannidis, IRCCS, Azienda Ospedaliero Universitaria S.Orsola Malpighi, Bologna, Italy, Italy

Dr. Cristina Papayannidis appears to be an outstanding candidate for the Best Researcher Award based on several key criteria:

Publication profile

scopus

Extensive Experience

Dr. Papayannidis has been deeply involved in clinical research and patient care in hematology since her early career. Her role as Dirigente Medico Ematologia at IRCCS Azienda Ospedaliero Universitaria di Bologna highlights her leadership in AML and ALL clinical trials.

High Research Output

She has authored over 130 publications and has been a principal or sub-investigator in more than 60 phase 1-3 clinical trials, showcasing her significant contributions to advancing hematology research.

Recognition and Influence

With an H-index of 34, she has made substantial impacts in her field. Her role as a speaker at over 300 national and international events, including prestigious conferences like ASH and EHA, underscores her influential presence in the hematological community.

Mentorship and Leadership

Her positions as a mentor in EHA Master Classes and member of various working groups demonstrate her commitment to guiding the next generation of researchers and shaping the future of hematology.

Professional Memberships

Memberships in esteemed organizations such as SIE, EHA, and AACR, and her role on the Hematological Malignancies Committee ESMO further reflect her prominent status and active participation in the scientific community.

Dr. Papayannidis’s extensive research experience, high publication volume, significant impact on clinical practice, and active involvement in mentorship and professional societies make her a highly suitable candidate for the Best Researcher Award.

Research focus

The research focus of the individuals associated with these articles centers on hematological malignancies and their management. They investigate advanced treatments and strategies for diseases like acute lymphoblastic leukemia (ALL), particularly in the context of drug therapies and stem cell transplantation. Key topics include evaluating the efficacy of ponatinib versus imatinib in treating Philadelphia chromosome-positive ALL, using ponatinib to prevent relapse after transplantation, and assessing the impact of inotuzumab ozogamicin on outcomes and complications in refractory cases. Their work contributes to improving therapeutic approaches and patient outcomes in hematology. 🩺💉🔬

Publication top notes

Managing Patients with Hypereosinophilic Syndrome: A Statement from the Italian Society of Allergy, Asthma, and Clinical Immunology (SIAAIC)

Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission †

Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease